Accelerating clinical development requires more than speed, it demands a careful balance between innovation, scientific rigor, and regulatory confidence.
In this case study, discover how Phastar partnered with a biotechnology company to develop an ambitious seamless Phase 2b/3 clinical trial strategy designed to support a critical FDA Type C meeting and accelerate progression into Phase 3.
Faced with adaptive design complexities, tight timelines, and significant regulatory scrutiny, the client needed a partner capable of delivering robust statistical solutions while maintaining development momentum.
Phastar provided strategic design expertise, regulatory alignment, and agile collaboration to transform a highly complex study concept into a credible, FDA-ready development pathway.
Download the case study to learn how:
- Adaptive Phase 2b/3 trial designs were aligned with FDA expectations
- Interim dose-selection strategies were implemented while preserving study integrity
- Statistical risks were identified and mitigated early
- Endpoints were aligned across development phases
- Regulatory readiness was strengthened through integrated planning
- Early analysis and reporting strategies reduced downstream risk
